Anemias:
Indications for: FERRLECIT
Iron deficiency anemia in patients with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy.
Adult Dosage:
Give by IV infusion (diluted) or slow IV inj (undiluted). 125mg infused over 1 hour or by slow IV inj (at a rate of up to 12.5mg/min). Minimum cumulative dose: 1g given over 8 sequential dialysis sessions; usual max: 125mg/dose.
Children Dosage:
<6yrs: not established. Give by IV infusion (diluted) over 1 hour. ≥6yrs: 1.5mg/kg per dose at 8 sequential dialysis sessions; max: 125mg/dose.
FERRLECIT Warnings/Precautions:
Risk of serious hypersensitivity reactions; monitor during and after administration for ≥30mins. Have personnel and resuscitative equipment readily available. Iron overload. Periodically monitor hematologic and iron parameters, and BP during and after administration. Elderly. Neonates/infants: risk of serious adverse reactions due to benzyl alcohol. Pregnancy, nursing mothers: consider alternative therapies without benzyl alcohol.
FERRLECIT Classification:
Hematinic.
FERRLECIT Interactions:
May reduce absorption of concomitant oral iron preparations.
Adverse Reactions:
Nausea, vomiting, diarrhea, inj site reaction, hypotension, cramps, hypertension, dizziness, dyspnea, chest pain, leg cramps, and pain; in children: also headache, tachycardia; hypersensitivity reactions.
How Supplied:
Single-dose vials (5mL)—10
